Serum kynurenine metabolites might not be associated with risk factors of treatment-resistant schizophrenia
Authors:
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 145, 339-346
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Multi-site genetic analysis of diffusion images and voxelwise heritability analysis: A pilot project of the ENIGMA–DTI working groupNeuroImage, 2013
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common PathwaySchizophrenia Bulletin, 2009
- Kynurenine pathway in psychosis: evidence of increased tryptophan degradationJournal of Psychopharmacology, 2008
- Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approachBMC Psychiatry, 2007
- Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brainJournal of Neural Transmission, 2006
- Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophreniaSchizophrenia Research, 2005
- Atypical antipsychotics and the relevance of glutamate and serotoninEuropean Neuropsychopharmacology, 2004
- Acute tryptophan and serotonin depletion using an optimized tryptophan-free protein–carbohydrate mixture in the adult ratNeurochemistry International, 2004
- The Emerging Role of Glutamate in the Pathophysiology and Treatment of SchizophreniaAmerican Journal of Psychiatry, 2001
- Suicide, Serotonin, and the BrainCrisis, 2001